By this acquisition, STADA further expands its presence in the important biosimilar sector. Subject to the approval of the competition authorities, STADA will acquire a further 35.48% of the shares from current co-shareholders and hold 51.34 % of BIOCEUTICALS Arzneimittel AG. BIOCEUTICALS Arzneimittel AG produces the substance Erythropoetin and markets it in particular by licensing it to STADAPHARM and other third parties.
METIS team includes Dr. Heinrich von Bünau (lead), Dr. Felix Dette, Bettine Jankowski, Jakob Sons (all corporate law/M&A). A team of the law firm Commero LLP, Frankfurt/M., under the lead by Dr. Dominique Wagner advises in relation to the merger control proceedings
